Trial Outcomes & Findings for A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease (NCT NCT05744401)

Last Updated: 2026-02-25

Results Overview

Adverse Events are any untoward medical occurrence in a participant enrolled in this study, including side effects, injury, toxicity, sensitivity reaction, intercurrent illnesses, clinically significant physical exam signs, or sudden death, whether or not it is considered related to the study drug.

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

197 participants

Primary outcome timeframe

From the Screening period and throughout the treatment period until the end of study participation, up to 49 weeks.

Results posted on

2026-02-25

Participant Flow

This was a long term extension to the AL002-2 parent study, where participants were required to complete the planned treatment period in AL002-2.

Participants received AL002 at final doses of 15 mg/kg, 40 mg/kg, or 60 mg/kg in the parent study. Participants who were randomized to active treatment in the parent study (Study AL002-2) remained at their previously assigned dose during this long-term extension study. Participants who were randomized to the placebo group in the parent study (Study AL002-2) were enrolled into the Titration Cohort

Participant milestones

Participant milestones
Measure	AL002 15 mg/kg Subjects are receiving 15 mg/kg of AL002 every 4 weeks	AL002 40 mg/kg Subjects are receiving 40 mg/kg of AL002 every 4 weeks	AL002 60 mg/kg Subjects are receiving 60 mg/kg of AL002 every 4 weeks	Titration Cohort The titration cohort will receive an initial starting dose of 6 mg/kg that will be increased to the target dose of 60 mg/kg. The subject will receive two doses of 6 mg/kg (Day 1/Week 1 and Week 5). The subject will receive two doses of 15 mg/kg (Week 9 and Week 13). The subject will receive two doses of 40 mg/kg (Week 17 and Week 21). Lastly, the subject will receive a dose of 60 mg/kg for the remainder of the study (Week 25 through the final dosing visit)
Overall Study STARTED	41	49	43	64
Overall Study COMPLETED	4	7	5	3
Overall Study NOT COMPLETED	37	42	38	61

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	AL002 15 mg/kg n=89 Participants Subjects are receiving 15 mg/kg of AL002 every 4 weeks	AL002 40 mg/kg n=87 Participants Subjects are receiving 40 mg/kg of AL002 every 4 weeks	AL002 60 mg/kg n=92 Participants Subjects are receiving 60 mg/kg of AL002 every 4 weeks	Titration Cohort n=64 Participants The titration cohort will receive an initial starting dose of 6 mg/kg that will be increased to the target dose of 60 mg/kg. The subject will receive two doses of 6 mg/kg (Day 1/Week 1 and Week 5). The subject will receive two doses of 15 mg/kg (Week 9 and Week 13). The subject will receive two doses of 40 mg/kg (Week 17 and Week 21). Lastly, the subject will receive a dose of 60 mg/kg for the remainder of the study (Week 25 through the final dosing visit)	Total n=332 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=24 Participants	0 Participants n=20 Participants	0 Participants n=40 Participants	0 Participants n=565 Participants	0 Participants n=349 Participants
Age, Categorical Between 18 and 65 years	23 Participants n=24 Participants	24 Participants n=20 Participants	16 Participants n=40 Participants	9 Participants n=565 Participants	72 Participants n=349 Participants
Age, Categorical >=65 years	66 Participants n=24 Participants	63 Participants n=20 Participants	76 Participants n=40 Participants	55 Participants n=565 Participants	260 Participants n=349 Participants
Sex: Female, Male Female	43 Participants n=24 Participants	49 Participants n=20 Participants	44 Participants n=40 Participants	28 Participants n=565 Participants	164 Participants n=349 Participants
Sex: Female, Male Male	46 Participants n=24 Participants	38 Participants n=20 Participants	48 Participants n=40 Participants	36 Participants n=565 Participants	168 Participants n=349 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=24 Participants	0 Participants n=20 Participants	0 Participants n=40 Participants	0 Participants n=565 Participants	0 Participants n=349 Participants
Race (NIH/OMB) Asian	0 Participants n=24 Participants	0 Participants n=20 Participants	2 Participants n=40 Participants	0 Participants n=565 Participants	2 Participants n=349 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=24 Participants	0 Participants n=20 Participants	0 Participants n=40 Participants	0 Participants n=565 Participants	0 Participants n=349 Participants
Race (NIH/OMB) Black or African American	3 Participants n=24 Participants	0 Participants n=20 Participants	0 Participants n=40 Participants	0 Participants n=565 Participants	3 Participants n=349 Participants
Race (NIH/OMB) White	80 Participants n=24 Participants	85 Participants n=20 Participants	87 Participants n=40 Participants	62 Participants n=565 Participants	314 Participants n=349 Participants
Race (NIH/OMB) More than one race	0 Participants n=24 Participants	0 Participants n=20 Participants	0 Participants n=40 Participants	1 Participants n=565 Participants	1 Participants n=349 Participants
Race (NIH/OMB) Unknown or Not Reported	6 Participants n=24 Participants	2 Participants n=20 Participants	3 Participants n=40 Participants	1 Participants n=565 Participants	12 Participants n=349 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	4 Participants n=24 Participants	5 Participants n=20 Participants	4 Participants n=40 Participants	3 Participants n=565 Participants	16 Participants n=349 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	79 Participants n=24 Participants	79 Participants n=20 Participants	85 Participants n=40 Participants	61 Participants n=565 Participants	304 Participants n=349 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	6 Participants n=24 Participants	3 Participants n=20 Participants	3 Participants n=40 Participants	0 Participants n=565 Participants	12 Participants n=349 Participants
Age, Customized Mean age of the study participants	69.7 Years STANDARD_DEVIATION 8.26 • n=24 Participants	69.2 Years STANDARD_DEVIATION 7.93 • n=20 Participants	70.7 Years STANDARD_DEVIATION 7.37 • n=40 Participants	72.8 Years STANDARD_DEVIATION 7.48 • n=565 Participants	70.4 Years STANDARD_DEVIATION 7.86 • n=349 Participants

PRIMARY outcome

Timeframe: From the Screening period and throughout the treatment period until the end of study participation, up to 49 weeks.

Outcome measures

Outcome measures
Measure	AL002 15 mg/kg n=41 Participants Subjects are receiving 15 mg/kg of AL002 every 4 weeks	AL002 40 mg/kg n=49 Participants Subjects are receiving 40 mg/kg of AL002 every 4 weeks	AL002 60 mg/kg n=43 Participants Subjects are receiving 60 mg/kg of AL002 every 4 weeks	Titration Cohort n=64 Participants The titration cohort will receive an initial starting dose of 6 mg/kg that will be increased to the target dose of 60 mg/kg. The subject will receive two doses of 6 mg/kg (Day 1/Week 1 and Week 5). The subject will receive two doses of 15 mg/kg (Week 9 and Week 13). The subject will receive two doses of 40 mg/kg (Week 17 and Week 21). Lastly, the subject will receive a dose of 60 mg/kg for the remainder of the study (Week 25 through the final dosing visit)
Safety and Tolerability as Measured by Number of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs). TEAE: Death	0 Occurrence of Adverse Event	0 Occurrence of Adverse Event	1 Occurrence of Adverse Event	0 Occurrence of Adverse Event
Safety and Tolerability as Measured by Number of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs). TEAE: Severe	1 Occurrence of Adverse Event	0 Occurrence of Adverse Event	2 Occurrence of Adverse Event	4 Occurrence of Adverse Event
Safety and Tolerability as Measured by Number of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs). TEAE: Moderate	5 Occurrence of Adverse Event	3 Occurrence of Adverse Event	11 Occurrence of Adverse Event	11 Occurrence of Adverse Event
Safety and Tolerability as Measured by Number of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs). TEAE: Mild	10 Occurrence of Adverse Event	17 Occurrence of Adverse Event	19 Occurrence of Adverse Event	21 Occurrence of Adverse Event
Safety and Tolerability as Measured by Number of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs). Treatment-Related TEAE: Death	0 Occurrence of Adverse Event	0 Occurrence of Adverse Event	0 Occurrence of Adverse Event	0 Occurrence of Adverse Event
Safety and Tolerability as Measured by Number of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs). Treatment-Related TEAE: Severe	1 Occurrence of Adverse Event	0 Occurrence of Adverse Event	0 Occurrence of Adverse Event	2 Occurrence of Adverse Event
Safety and Tolerability as Measured by Number of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs). Treatment-Related TEAE: Moderate	2 Occurrence of Adverse Event	1 Occurrence of Adverse Event	2 Occurrence of Adverse Event	4 Occurrence of Adverse Event
Safety and Tolerability as Measured by Number of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs). Treatment-Related TEAE: Mild	1 Occurrence of Adverse Event	4 Occurrence of Adverse Event	7 Occurrence of Adverse Event	10 Occurrence of Adverse Event

PRIMARY outcome

Timeframe: From the Screening period and throughout the treatment period until the end of study participation, up to 49 weeks.

Outcome measures

Outcome measures
Measure	AL002 15 mg/kg n=41 Participants Subjects are receiving 15 mg/kg of AL002 every 4 weeks	AL002 40 mg/kg n=49 Participants Subjects are receiving 40 mg/kg of AL002 every 4 weeks	AL002 60 mg/kg n=43 Participants Subjects are receiving 60 mg/kg of AL002 every 4 weeks	Titration Cohort n=64 Participants The titration cohort will receive an initial starting dose of 6 mg/kg that will be increased to the target dose of 60 mg/kg. The subject will receive two doses of 6 mg/kg (Day 1/Week 1 and Week 5). The subject will receive two doses of 15 mg/kg (Week 9 and Week 13). The subject will receive two doses of 40 mg/kg (Week 17 and Week 21). Lastly, the subject will receive a dose of 60 mg/kg for the remainder of the study (Week 25 through the final dosing visit)
Safety and Tolerability as Measured by Number of Adverse Events of Special Interest and Serious Adverse Events Treatment-Emergent Adverse Event of Special Interest	2 Occurrence of Adverse Event	2 Occurrence of Adverse Event	5 Occurrence of Adverse Event	11 Occurrence of Adverse Event
Safety and Tolerability as Measured by Number of Adverse Events of Special Interest and Serious Adverse Events Treatment-Related Adverse Events of Special Interest	2 Occurrence of Adverse Event	2 Occurrence of Adverse Event	5 Occurrence of Adverse Event	11 Occurrence of Adverse Event
Safety and Tolerability as Measured by Number of Adverse Events of Special Interest and Serious Adverse Events Treatment-Emergent Serious Adverse Event (TESAE)	0 Occurrence of Adverse Event	0 Occurrence of Adverse Event	3 Occurrence of Adverse Event	7 Occurrence of Adverse Event
Safety and Tolerability as Measured by Number of Adverse Events of Special Interest and Serious Adverse Events Treatment-Related Serious Adverse Event	0 Occurrence of Adverse Event	0 Occurrence of Adverse Event	0 Occurrence of Adverse Event	3 Occurrence of Adverse Event

PRIMARY outcome

Timeframe: From the Screening period and throughout the treatment period until the end of study completion, up to 49 weeks

Evaluation of vital signs (blood pressure, pulse, temperature), clinical laboratory results (hematology, biochemistry, urinalysis), and findings from physical, neurological, ophthalmological examinations, and electrocardiograms.

Outcome measures

Outcome measures
Measure	AL002 15 mg/kg n=41 Participants Subjects are receiving 15 mg/kg of AL002 every 4 weeks	AL002 40 mg/kg n=49 Participants Subjects are receiving 40 mg/kg of AL002 every 4 weeks	AL002 60 mg/kg n=43 Participants Subjects are receiving 60 mg/kg of AL002 every 4 weeks	Titration Cohort n=64 Participants The titration cohort will receive an initial starting dose of 6 mg/kg that will be increased to the target dose of 60 mg/kg. The subject will receive two doses of 6 mg/kg (Day 1/Week 1 and Week 5). The subject will receive two doses of 15 mg/kg (Week 9 and Week 13). The subject will receive two doses of 40 mg/kg (Week 17 and Week 21). Lastly, the subject will receive a dose of 60 mg/kg for the remainder of the study (Week 25 through the final dosing visit)
Safety and Tolerability as Measured by the Number of Cases of Abnormal Vital Signs, Clinical Laboratory Results and Findings From Physical, Neurological, Ophthalmological Examinations and Electrocardiograms.	0 Occurrence of Abnormal Findings	0 Occurrence of Abnormal Findings	0 Occurrence of Abnormal Findings	0 Occurrence of Abnormal Findings

PRIMARY outcome

Timeframe: From the Screening period and throughout the treatment period until the end of the study participation up to 49 weeks.

Two versions of the C-SSRS were used in the parent study: a Screening/Baseline version and a Since Last Visit version. The Screening/Baseline version of the C-SSRS assesses the lifetime suicidal ideation and behavior and non-suicidal self-injurious behavior, the suicidal ideation in the past 6 months, and suicidal behavior and non-suicidal self-injurious behavior in the past two years. The C-SSRS uses a point scale where a higher score indicates a greater risk of suicidality.

Outcome measures

Outcome measures
Measure	AL002 15 mg/kg n=41 Participants Subjects are receiving 15 mg/kg of AL002 every 4 weeks	AL002 40 mg/kg n=49 Participants Subjects are receiving 40 mg/kg of AL002 every 4 weeks	AL002 60 mg/kg n=43 Participants Subjects are receiving 60 mg/kg of AL002 every 4 weeks	Titration Cohort n=64 Participants The titration cohort will receive an initial starting dose of 6 mg/kg that will be increased to the target dose of 60 mg/kg. The subject will receive two doses of 6 mg/kg (Day 1/Week 1 and Week 5). The subject will receive two doses of 15 mg/kg (Week 9 and Week 13). The subject will receive two doses of 40 mg/kg (Week 17 and Week 21). Lastly, the subject will receive a dose of 60 mg/kg for the remainder of the study (Week 25 through the final dosing visit)
To Evaluate the Long-term Safety and Tolerability of AL002, by Assessing the Number of Suicidal Risk Events Using the Columbia-Suicide Severity Rating Scale (C-SSRS)	1 Number of Participants	0 Number of Participants	0 Number of Participants	0 Number of Participants

PRIMARY outcome

Timeframe: Screening, Week 9, Week 17, Week 25, Week 33, Week 41, End of Study visit, and Early Termination visit, if applicable up to 49 weeks

Population: The analysis population for this outcome includes the parent study and the long term extension.

Among the brain abnormalities detected on MRI are ARIA, which are believed to reflect leakage of proteinaceous fluid or other blood products in the leptomeninges or brain parenchyma. The term ARIA was originally coined to describe specific brain abnormalities seen on MRI in anti-amyloid clinical trials. Specifically, according to the convention developed to describe ARIA occurring in clinical trials of anti-amyloid immunotherapies, ARIA-E refers to MRI findings of vasogenic edema and leptomeningeal/sulcal effusion.

Outcome measures

Outcome measures
Measure	AL002 15 mg/kg n=97 Participants Subjects are receiving 15 mg/kg of AL002 every 4 weeks	AL002 40 mg/kg n=94 Participants Subjects are receiving 40 mg/kg of AL002 every 4 weeks	AL002 60 mg/kg n=77 Participants Subjects are receiving 60 mg/kg of AL002 every 4 weeks	Titration Cohort n=64 Participants The titration cohort will receive an initial starting dose of 6 mg/kg that will be increased to the target dose of 60 mg/kg. The subject will receive two doses of 6 mg/kg (Day 1/Week 1 and Week 5). The subject will receive two doses of 15 mg/kg (Week 9 and Week 13). The subject will receive two doses of 40 mg/kg (Week 17 and Week 21). Lastly, the subject will receive a dose of 60 mg/kg for the remainder of the study (Week 25 through the final dosing visit)
To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-E by Assessing the Number of Participants With ARIA-E Events	23 Number of Participants	23 Number of Participants	17 Number of Participants	7 Number of Participants

PRIMARY outcome

Timeframe: Screening, Week 9, Week 17, Week 25, Week 33, Week 41, End of Study visit, and Early Termination visit, if applicable up to 49 weeks

Population: The analysis population for this outcome includes the parent study and the long term extension.

Among the brain abnormalities detected on MRI are ARIA, which are believed to reflect leakage of proteinaceous fluid or other blood products int the leptomeninges or brain parenchyma. The term ARIA was originally coined to describe specific brain abnormalities seen on MRI in anti-amyloid clinical trials. Specifically, according to the convention developed to describe ARIA occurring in clinical trials of anti-amyloid immunotherapies, ARIA-H refers to MRI findings of cerebral microhemorrhages, leptomeningeal hemosiderosis, and cerebral macrohemorrhages.

Outcome measures

Outcome measures
Measure	AL002 15 mg/kg n=97 Participants Subjects are receiving 15 mg/kg of AL002 every 4 weeks	AL002 40 mg/kg n=94 Participants Subjects are receiving 40 mg/kg of AL002 every 4 weeks	AL002 60 mg/kg n=77 Participants Subjects are receiving 60 mg/kg of AL002 every 4 weeks	Titration Cohort n=64 Participants The titration cohort will receive an initial starting dose of 6 mg/kg that will be increased to the target dose of 60 mg/kg. The subject will receive two doses of 6 mg/kg (Day 1/Week 1 and Week 5). The subject will receive two doses of 15 mg/kg (Week 9 and Week 13). The subject will receive two doses of 40 mg/kg (Week 17 and Week 21). Lastly, the subject will receive a dose of 60 mg/kg for the remainder of the study (Week 25 through the final dosing visit)
To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-H by Assessing the Number of Participants With ARIA-H Events Incidence of ARIA-H	30 Number of Participants	30 Number of Participants	25 Number of Participants	9 Number of Participants
To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-H by Assessing the Number of Participants With ARIA-H Events Incidence of Microhemorrhages	17 Number of Participants	18 Number of Participants	18 Number of Participants	6 Number of Participants
To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-H by Assessing the Number of Participants With ARIA-H Events Incidence of Superficial Siderosis	12 Number of Participants	12 Number of Participants	6 Number of Participants	2 Number of Participants
To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-H by Assessing the Number of Participants With ARIA-H Events Incidence of Macrohemorrhages	1 Number of Participants	0 Number of Participants	1 Number of Participants	1 Number of Participants

Adverse Events

AL002 15 mg/kg

Serious events: 0 serious events

Other events: 16 other events

Deaths: 0 deaths

AL002 40 mg/kg

Serious events: 0 serious events

Other events: 12 other events

Deaths: 0 deaths

AL002 60 mg/kg

Serious events: 3 serious events

Other events: 33 other events

Deaths: 1 deaths

Titration Cohort

Serious events: 9 serious events

Other events: 30 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	AL002 15 mg/kg n=41 participants at risk Subjects are receiving 15 mg/kg of AL002 every 4 weeks	AL002 40 mg/kg n=49 participants at risk Subjects are receiving 40 mg/kg of AL002 every 4 weeks	AL002 60 mg/kg n=43 participants at risk Subjects are receiving 60 mg/kg of AL002 every 4 weeks	Titration Cohort n=64 participants at risk The titration cohort will receive an initial starting dose of 6 mg/kg that will be increased to the target dose of 60 mg/kg. The subject will receive two doses of 6 mg/kg (Day 1/Week 1 and Week 5). The subject will receive two doses of 15 mg/kg (Week 9 and Week 13). The subject will receive two doses of 40 mg/kg (Week 17 and Week 21). Lastly, the subject will receive a dose of 60 mg/kg for the remainder of the study (Week 25 through the final dosing visit)
Immune system disorders Anaphylactic Reaction	0.00% 0/41 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/49 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/43 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	1.6% 1/64 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks
Infections and infestations COVID-19	0.00% 0/41 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/49 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/43 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	1.6% 1/64 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks
Injury, poisoning and procedural complications Clavicle Fracture	0.00% 0/41 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/49 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/43 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	1.6% 1/64 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks
Injury, poisoning and procedural complications Fall	0.00% 0/41 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/49 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/43 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	1.6% 1/64 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks
Injury, poisoning and procedural complications Femoral Neck Fracture	0.00% 0/41 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/49 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	2.3% 1/43 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/64 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks
Injury, poisoning and procedural complications Hip Fracture	0.00% 0/41 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/49 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/43 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	1.6% 1/64 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks
Musculoskeletal and connective tissue disorders Musculoskeletal Chest Pain	0.00% 0/41 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/49 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/43 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	1.6% 1/64 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Plasma Cell Myeloma	0.00% 0/41 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/49 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	2.3% 1/43 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/64 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks
Nervous system disorders Amyloid-related Imaging Abnormality: Microhaemorrhages and Haemosiderin Deposits	0.00% 0/41 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/49 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/43 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	1.6% 1/64 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks
Nervous system disorders Cerebral Infarction	0.00% 0/41 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/49 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/43 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	1.6% 1/64 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks
Nervous system disorders Syncope	0.00% 0/41 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/49 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/43 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	1.6% 1/64 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks
Respiratory, thoracic and mediastinal disorders Acute Respiratory Failure	0.00% 0/41 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/49 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	2.3% 1/43 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks	0.00% 0/64 • Adverse events were collected from the time the participant signed the informed consent form until the end of study participation up to 57 weeks

Other adverse events

Additional Information

Alector Medical Information

Alector

Phone: 650-826-2454

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Alector's agreements with principal investigators may vary but will not prohibit any investigator from publishing. Alector supports the publication of the results from all centers in a multi-center trial, and its agreements include provisions to enable the multi-center publication to occur before publication of data from a single site.
Publication restrictions are in place

Restriction type: OTHER